News Archive

Sisters Rebecca Kirkland and Mary Trent Jones are no strangers to volunteering, spending decades serving on boards, with Rebecca on the Duke University Board of Trustees and the D

2024 marks the 10-year anniversary of PCORnet® — a national patient-centered clinical research network developed with funding from the Patient Centered Outcomes Research Institute (PCORI) to support a transformational shift toward national-scale, patient-centered comparative clinical effectiveness research. What started as a vision to bypass the traditional silos hindering research insights has since become a powerful infrastructure with proven success across hundreds of studies seeking fast, representative answers that are meaningful to patients and caregivers. The DCRI has played a major role in the success of PCORnet.

A new publication developed in collaboration by CTTI, the Duke Clinical Research Institute (DCRI), the Duke Margolis Institute for Health Policy, and Protas published in Trials highlights the current barriers to clinical trial transformation, areas of improvement, and actions needed to transform clinical evidence generation in the United States to better align with clinical care demands. A modern clinical trial infrastructure should prioritize trial accessibility, answer relevant study questions reliably, respond to public health emergencies rapidly, and more.

Faculty members and fellows of the Duke Clinical Research Institute (DCRI) shared their expertise during the European Society of Cardiology Congress (ESC) in London, Aug. 30-Sept. 2. Late-breaking trial results presented by DCRI faculty at the meeting offered new insights into drug and device efficacy and capabilities.

Allyx Therapeutics has announced that the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics and potential therapeutic response in patients with Parkinson’s disease. ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy. Allyx Therapeutics is a clinical-stage biotechnology company working to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases.

Wearable, long-term continuous heart monitors helped identify 52% more cases of atrial fibrillation compared to usual care, but that did not lead to a reduction in hospitalizations due to stroke, according to a study led by the Duke Clinical Research Institute.

A new event series hosted by i-Cubed promises to forge connections and accelerate promising startups to expedite breakthroughs and improve efficiencies in clinical res

New evidence and results from eight studies based on data from the IPF-PRO/ILD-PRO Registry was shared by the Duke Clinical Research Institute (DCRI) and its collaborators at the American Tho

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit in taking montelukast at a dosa

Three Duke Clinical Research Institute faculty members were honored by the Duke School of Medicine during the school’s annual faculty awards ceremony on Tuesday, May 14.